CompletedPhase 3NCT02746991

Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis

Studying Infectious panuveitis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
EyePoint Pharmaceuticals, Inc.
Principal Investigator
Flavio Leonin Jr., MD
EyePoint Pharmaceuticals, Inc.
Intervention
Sham Injection(drug)
Enrollment
153 enrolled
Eligibility
18 years · All sexes
Timeline
20152019

Study locations (15)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02746991 on ClinicalTrials.gov
← Back to all trials